The current status of combination therapy of Chronic Hepatitis B

European Review for Medical and Pharmacological Sciences

Volumn 17, Issue 15, 2013, Pages 2023-2031

  Chen, E Q ^a,b   Tang, H ^a,b  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Advantage; Candidates; Chronic hepatitis B; Combination therapy; Strategy

Indexed keywords

ADEFOVIR; ALPHA INTERFERON; ENTECAVIR; LAMIVUDINE; PEGINTERFERON ALPHA2B; TELBIVUDINE; TENOFOVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; DECOMPENSATED LIVER CIRRHOSIS; DRUG RESISTANCE; HEPATITIS B; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER TRANSPLANTATION; MIXED INFECTION; MONOTHERAPY; PREVALENCE; TREATMENT RESPONSE; ANTIVIRAL RESISTANCE; COINFECTION; DRUG COMBINATION; HEPATITIS B, CHRONIC; HIV INFECTIONS; LIVER CIRRHOSIS;

ANTIVIRAL AGENTS; COINFECTION; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS;

EID: 84884234319     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (84)

1. LIAW YF, CHU CM. Hepatitis B virus infection. Lancet 2009; 373: 582-592.
2. LOK AS, MCMAHON BJ. Chronic hepatitis B. Hepatology 2007; 45: 507-539. (Pubitemid 46374607)
3. LIN CL, KAO JH. Recent advances in the treatment of chronic hepatitis B. Expert Opin Pharmacother 2011; 12: 2025-2040.
4. ZHANG NP, REIJNDERS JG, PERQUIN M, HANSEN BE, JANSSEN HL. Frequency and clinical outcomes of flares related to nucleos(t)ide analogue therapy in patients with chronic hepatitis B. J Viral Hepat 2011; 18: e252-257.
5. TANG H, MCLACHLAN A. Transcriptional regulation of hepatitis B virus by nuclear hormone receptors is a critical determinant of viral tropism. Proc Natl Acad Sci U S A 2001; 98: 1841-1846. (Pubitemid 32165585)
6. ILOEJE UH, YANG HI, SU J, JEN CL, YOU SL, CHEN CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686. (Pubitemid 43374518)
7. CHEN CJ, YANG HI, SU J, JEN CL, YOU SL, LU SN, HUANG GT, ILOEJE UH. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006; 295: 65-73. (Pubitemid 43042691)
8. VIGANO M, LAMPERTICO P. Antiviral drugs for HBV liver disease. Expert Opin Biol Ther 2011; 11: 285-300.
9. CARROLL MB. The impact of biologic response modifiers on hepatitis B virus infection. Expert Opin Biol Ther 2011; 11: 533-544.
10. LONG Y, CHEN E, LIU C, HUANG F, ZHOU T, HE F, LIU L, LIU F, TANG H. The correlation of hepatocyte nuclear factor 4 alpha and 3 beta with hepatitis B virus replication in the liver of chronic hepatitis B patients. J Viral Hepat 2009; 16: 537-546.
11. PAPATHEODORIDIS GV, MANOLAKOPOULOS S, TOULOUMI G, VOURLI G, RAPTOPOULOU-GIGI M, VAFIADIS-ZOUMBOULI I, VASILIADIS T, MIMIDIS K, GOGOS C, KETIKOGLOU I, MANESIS EK. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study. Gut 2011; 60: 1109-1116.
12. COFFIN CS, MULROONEY-COUSINS PM, VAN MARLE G, ROBERTS JP, MICHALAK TI, TERRAULT NA. Hepatitis B virus quasispecies in hepatic and extrahepatic viral reservoirs in liver transplant recipients on prophylactic therapy. Liver Transpl 2011; 17: 955-962.
13. SHAMLIYAN TA, MACDONALD R, SHAUKAT A, TAYLOR BC, YUAN JM, JOHNSON JR, TACKLIND J, RUTKS I, KANE RL, WILT TJ. Antiviral therapy for adults with chronic hepatitis B: a systematic review for a National Institutes of Health Consensus Development Conference. Ann Intern Med 2009; 150: 111-124.
14. WANG Z, WU XL, ZENG WZ, XU H, ZHANG Y, QIN JP, JIANG MD. Lamivudine plus adefovir is a good option for chronic hepatitis B patients with viral relapse after cessation of lamivudine treatment. Virol J 2011; 8: 388
15. CHEN EQ, ZHOU TY, TANG H. Combination of telbivudine and adefovir dipivoxil therapy in chronic hepatitis B patients with poor response to adefovir dipivoxil monotherapy. Int J Inf Dis 2010; 14: S18-S.
16. WANG LC, CHEN EQ, CAO J, LIU L, WANG JR, LEI BJ, TANG H. Combination of Lamivudine and adefovir therapy in HBeAg-positive chronic hepatitis B patients with poor response to adefovir monotherapy. J Viral Hepat 2010; 17: 178-184.
17. CHON YE, KIM SU, LEE CK, HEO J, KIM JK, YOON KT, CHO M, LEE KS, KIM DH, CHOI EH, PARK JY, KIM DO Y, CHON CY, HAN KH, AHN SH. Partial virological response to entecavir in treatment-naive patients with chronic hepatitis B. Antivir Ther 2011; 16: 469-477.
18. BENNETT JC, PLUM F, CECIL RL. Cecil textbook of medicine. 20th ed./edited by J. Claude Bennett, Fred Plum. ed. Philadelphia; London: Saunders; 1996.
19. BUSTER EH, VAN ERPECUM KJ, SCHALM SW, ZAAIJER HL, BROUWER JT, GELDERBLOM HC, DE KNEGT RJ, MINKE BAKKER C, REESINK HW, JANSSEN HL. Treatment of chronic hepatitis B virus infection - Dutch national guidelines. Neth J Med 2008; 66: 292-306.
20. TEN KATE FJ, SCHALM SW, WILLEMSE PJ, BLOK AP, HEIJTINK RA, TERPSTRA OT. Course of hepatitis B and D virus infection in auxiliary liver grafts in hepatitis B-positive patients. A light-microscopic and immunohistochemical study. J Hepatol 1992; 14: 168-175.
21. The guideline of prevention and treatment for chronic hepatitis B (2010 version). Zhonghua Gan Zang Bing Za Zhi 2011; 19: 13-24.
22. SCOTT JD, MCMAHON B. Role of combination therapy in chronic hepatitis B. Curr Gastroenterol Rep 2009; 11: 28-36.
23. CHAN HL, LEUNG NW, HUI AY, WONG VW, LIEW CT, CHIM AM, CHAN FK, HUNG LC, LEE YT, TAM JS, LAM CW, SUNG JJ. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142: 240-250. (Pubitemid 40216241)
24. MARCELLIN P, LAU GK, BONINO F, FARCI P, HADZIYANNIS S, JIN R, LU ZM, PIRATVISUTH T, GERMANIDIS G, YURDAYDIN C, DIAGO M, GUREL S, LAI MY, BUTTON P, PLUCK N. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217. (Pubitemid 39296307)
25. BONINO F, MARCELLIN P, LAU GK, HADZIYANNIS S, JIN R, PIRATVISUTH T, GERMANIDIS G, YURDAYDIN C, DIAGO M, GUREL S, LAI MY, BRUNETTO MR, FARCI P, POPESCU M, MCCLOUD P. Predicting response to peginterferon alpha-2a, lamivudine and the two combined for HBeAg-negative chronic hepatitis B. Gut 2007; 56: 699-705. (Pubitemid 46662938)
26. WOO G, TOMLINSON G, NISHIKAWA Y, KOWGIER M, SHERMAN M, WONG DK, PHAM B, UNGAR WJ, EINARSON TR, HEATHCOTE EJ, KRAHN M. Tenofovir and entecavir are the most effective antiviral agents for chronic hepatitis B: a systematic review and Bayesian meta-analyses. Gastroenterology 2010; 139: 1218-1229.
27. SETO WK, YUEN MF, FUNG J, LAI CL. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B monoinfection. Hepatol Int 2011. [Epub ahead of print]
28. OSBORN M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist 2011; 4: 55-64.
29. YANG JX, LIU BM, LI XG, YAN CH, XU J, SUN XW, WANG YH, JIAO XJ, YAN L, DONG JP, HOU CS, ABUDUHEILILI X, LI T, ZHUANG H. Profile of HBV antiviral resistance mutations with distinct evolutionary pathways against nucleoside/nucleotide analogue treatment among Chinese chronic hepatitis B patients. Antivir Ther 2010; 15: 1171-1178.
30. LAMPERTICO P. Partial virological response to nucleos( t)ide analogues in naive patients with chronic hepatitis B: From guidelines to field practice. J Hepatol 2009; 50: 644-647.
31. LAI CL, GANE E, LIAW YF, HSU CW, THONGSAWAT S, WANG Y, CHEN Y, HEATHCOTE EJ, RASENACK J, BZOWEJ N, NAOUMOV NV, DI BISCEGLIE AM, ZEUZEM S, MOON YM, GOODMAN Z, CHAO G, CONSTANCE BF, BROWN NA. Telbivudine versus lamivudine in patients with chronic hepatitis B. N Engl J Med 2007; 357: 2576-2588. (Pubitemid 350294224)
32. LIAW YF, GANE E, LEUNG N, ZEUZEM S, WANG Y, LAI CL, HEATHCOTE EJ, MANNS M, BZOWEJ N, NIU J, HAN SH, HWANG SG, CAKALOGLU Y, TONG MJ, PAPATHEODORIDIS G, CHEN Y, BROWN NA, ALBANIS E, GALIL K, NAOUMOV NV. 2-Year GLOBE trial results: telbivudine Is superior to lamivudine in patients with chronic hepatitis B. Gastroenterology 2009; 136: 486-495.
33. RIJCKBORST V, SONNEVELD MJ, JANSSEN HL. Review article: chronic hepatitis B - anti-viral or immunomodulatory therapy? Aliment Pharmacol Ther 2011; 33: 501-513.
34. CHEN CH, LEE CM, HUNG CH, WANG JH, HU TH, CHANGCHIEN CS, LU SN. Hepatitis B virus genotype B results in better immediate, late and sustained responses to peginterferon-alfa in hepatitis-B-eantigen- positive patients. J Gastroenterol Hepatol 2011; 26: 461-468.
35. THOMPSON MA, ABERG JA, CAHN P, MONTANER JS, RIZZARDINI G, TELENTI A, GATELL JM, GUNTHARD HF, HAMMER SM, HIRSCH MS, JACOBSEN DM, REISS P, RICHMAN DD, VOLBERDING PA, YENI P, SCHOOLEY RT. Antiretroviral treatment of adult HIV infection: 2010 recommendations of the International AIDS Society- USA panel. JAMA 2010; 304: 321-333.
36. CRAXI A. EASL Clinical Practice Guidelines: Management of hepatitis C virus infection. J Hepatol 2011; 55: 245-264.
37. WURSTHORN K, LUTGEHETMANN M, DANDRI M, VOLZ T, BUGGISCH P, ZOLLNER B, LONGERICH T, SCHIRMACHER P, METZLER F, ZANKEL M, FISCHER C, CURRIE G, BROSGART C, PETERSEN J. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44: 675-684. (Pubitemid 44433724)
38. JACQUARD AC, NASSAL M, PICHOUD C, REN S, SCHULTZ U, GUERRET S, CHEVALLIER M, WERLE B, PEYROL S, JAMARD C, RIMSKY LT, TREPO C, ZOULIM F. Effect of a combination of clevudine and emtricitabine with adenovirus-mediated delivery of gamma interferon in the woodchuck model of hepatitis B virus infection. Antimicrob Agents Chemother 2004; 48: 2683-2692. (Pubitemid 38823442)
39. CHEN EQ, WANG LC, LEI J, XU L, TANG H. Metaanalysis: adefovir dipivoxil in combination with lamivudine in patients with lamivudine-resistant hepatitis B virus. Virol J 2009; 6: 163.
40. RANEY AK, KLINE EF, TANG H, MCLACHLAN A. Transcription and replication of a natural hepatitis B virus nucleocapsid promoter variant is regulated in vivo by peroxisome proliferators. Virology 2001; 289: 239-251. (Pubitemid 33141004)
41. WANG F, WANG H, SHEN H, MENG C, WENG X, ZHANG W. Evolution of hepatitis B virus polymerase mutations in a patient with HBeAg-positive chronic hepatitis B virus treated with sequential monotherapy and add-on nucleoside/nucleotide analogues. Clin Ther 2009; 31: 360-366.
42. WEI C, CHONG YT, WEN JZ, LI YW, LI G. Characterization of hepatitis virus B isolated from a multi-drug refractory patient. Virus Res 2011; 155: 254-258.
43. KURASHIGE N, OHKAWA K, HIRAMATSU N, OZE T, YAKUSHIJIN T, MOCHIZUKI K, HOSUI A, MIYAGI T, ISHIDA H, TATSUMI T, KANTO T, TAKEHARA T, HAYASHI N. Two types of drug-resistant hepatitis B viral strains emerging alternately and their susceptibility to combination therapy with entecavir and adefovir. Antivir Ther 2009; 14: 873-877.
44. LOCARNINI S. Primary resistance, multidrug resistance, and cross-resistance pathways in HBV as a consequence of treatment failure. Hepatol Int 2008; 2: 147-151. (Pubitemid 351650142)
45. LEE YS, CHUNG YH, KIM JA, KIM SE, SHIN JW, KIM KM, LIM YS, PARK NH, LEE HC, SUH DJ. Hepatitis B virus with the rtL80V/I mutation is associated with a poor response to adefovir dipivoxil therapy. Liver Int 2009; 29: 552-556.
46. ZHAO LS, QIN S, ZHOU TY, TANG H, LIU L, LEI BJ. DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of Cmyc. World J Gastroenterol 2000; 6: 239-243. (Pubitemid 30223603)
47. TANG H, BANKS KE, ANDERSON AL, MCLACHLAN A. Hepatitis B virus transcription and replication. Drug News Perspect 2001; 14: 325-334. (Pubitemid 32970829)
48. JIANG L, JIANG LS, CHENG NS, YAN LN. Current prophylactic strategies against hepatitis B virus recurrence after liver transplantation. World J Gastroenterol 2009; 15: 2489-99.
49. PIROTH L, MAHY S, POL S, CARRAT F, SENE D, ETIENNE M, LASCOUX-COMBE C, SIMON A, SCHMIT JL, CACOUB P. Current management and recommendations on hepatitis B therapy in HIV-coinfected patients. Hepatol Int 2011; [Epub ahead of print].
50. DEMING P, MCNICHOLL IR. Coinfection with human immunodeficiency virus and hepatitis C virus: challenges and therapeutic advances. Insights from the Society of Infectious Diseases Pharmacists. Pharmacotherapy 2011; 31: 357-368.
51. LAI CL, DIENSTAG J, SCHIFF E, LEUNG NW, ATKINS M, HUNT C, BROWN N, WOESSNER M, BOEHME R, CONDREAY L. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 2003; 36: 687-696. (Pubitemid 36337972)
52. LITWIN S, TOLL E, JILBERT AR, MASON WS. The competing roles of virus replication and hepatocyte death rates in the emergence of drug-resistant mutants: theoretical considerations. J Clin Virol 2005; 34(Suppl 1): S96-S107. (Pubitemid 43197756)
53. LIU TT, FANG Y, XIONG H, CHEN TY, NI ZP, LUO JF, ZHAO NQ, SHEN XZ. A case-control study of the relationship between hepatitis B virus DNA level and risk of hepatocellular carcinoma in Qidong, China. World J Gastroenterol 2008; 14: 3059-3063.
54. OHATA K, HAMASAKI K, TORIYAMA K, ISHIKAWA H, NAKAO K, EGUCHI K. High viral load is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis B virus infection. J Gastroenterol Hepatol 2004; 19: 670-675. (Pubitemid 38858201)
55. ZOULIM F. Mechanism of viral persistence and resistance to nucleoside and nucleotide analogs in chronic hepatitis B virus infection. Antiviral Res 2004; 64: 1-15. (Pubitemid 39307089)
56. WANG LC, CHEN EQ, CAO J, LIU L, ZHENG L, LI DJ, XU L, LEI XZ, LIU C, TANG H. De novo combination of lamivudine and adefovir versus entecavir monotherapy for the treatment of naive HBeAg-negative chronic hepatitis B patients. Hepatol Int 2011; 5: 671-676.
57. LIU K, LEI XZ, ZHAO LS, TANG H, LIU L, FENG P, LEI BJ. Tissue microarray for high-throughput analysis of gene expression profiles in hepatocellular carcinoma. World J Gastroenterol 2005; 11: 1369-1372. (Pubitemid 40425923)
58. JANSSEN HL, VAN ZONNEVELD M, SENTURK H, ZEUZEM S, AKARCA US, CAKALOGLU Y, SIMON C, SO TM, GERKEN G, DE MAN RA, NIESTERS HG, ZONDERVAN P, HANSEN B, SCHALM SW. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365: 123-129. (Pubitemid 40091801)
59. LAU GK, PIRATVISUTH T, LUO KX, MARCELLIN P, THONGSAWAT S, COOKSLEY G, GANE E, FRIED MW, CHOW WC, PAIK SW, CHANG WY, BERG T, FLISIAK R, MCCLOUD P, PLUCK N. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695. (Pubitemid 41007823)
60. LI WC, WANG MR, KONG LB, REN WG, ZHANG YG, NAN YM. Peginterferon alpha-based therapy for chronic hepatitis B focusing on HBsAg clearance or seroconversion: a meta-analysis of controlled clinical trials. BMC Infect Dis 2011; 11: 165.
61. PICCOLO P, LENCI I, DEMELIA L, BANDIERA F, PIRAS MR, ANTONUCCI G, NOSOTTI L, MARI T, DE SANTIS A, PONTI ML, SORBELLO O, IACOMI F, ANGELICO M. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen- negative chronic hepatitis B. Antivir Ther 2009; 14: 1165-1674.
62. MARCELLIN P, AVILA C, WURSTHORN K, CHUANG WL, LAU GK, PENG CY, GANE EJ, FAINBOIM H, MANNS MP, NV N. Telbivudine (LdT) plus peginterferon (pegIFN) in HBeAg-positive chronic hepatitis BVery potent antiviral efficacy but risk of peripheral neuropathy (PN). J Hepatol 2010; 52: S6-S7.
63. GAIA S, BARBON V, SMEDILE A, OLIVERO A, CARENZI S, LAGGET M, ALESSANDRIA C, RIZZETTO M, MARZANO A. Lamivudine-resistant chronic hepatitis B: an observational study on adefovir in monotherapy or in combination with lamivudine. J Hepatol 2008; 48: 540-547.
64. LAMPERTICO P, VIGANO M, MANENTI E, IAVARONE M, LUNGHI G, COLOMBO M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005; 42: 1414-1419. (Pubitemid 43260045)
65. RAPTI I, DIMOU E, MITSOULA P, HADZIYANNIS SJ. Adding-on versus switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007; 45: 307-313. (Pubitemid 46374587)
66. YATSUJI H, SUZUKI F, SEZAKI H, AKUTA N, SUZUKI Y, KAWAMURA Y, HOSAKA T, KOBAYASHI M, SAITOH S, ARASE Y, IKEDA K, WATAHIKI S, IWASAKI S, KUMADA H. Low risk of adefovir resistance in lamivudine-resistant chronic hepatitis B patients treated with adefovir plus lamivudine combination therapy: two-year follow-up. J Hepatol 2008; 48: 923-931.
67. LAMPERTICO P, VIGANO M, MANENTI E, IAVARONE M, SABLON E, COLOMBO M. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology 2007; 133: 1445-1451. (Pubitemid 350047463)
68. PETERS MG, HANN HW H, MARTIN P, HEATHCOTE EJ, BUGGISCH P, RUBIN R, BOURLIERE M, KOWDLEY K, TREPO C, GRAY DF D, SULLIVAN M, KLEBER K, EBRAHIMI R, XIONG S, BROSGARt CL. Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology 2004; 126: 91-101. (Pubitemid 38040727)
69. LIN Y, NOMURA T, YAMASHITA T, DORJSUREN D, TANG H, MURAKAMI S. The transactivation and p53-interacting functions of hepatitis B virus X protein are mutually interfering but distinct. Cancer Res 1997; 57: 5137-5142. (Pubitemid 27498132)
70. MUTIMER D. Tenofovir salvage for nucleoside experienced patients: muddy waters? Gut 2011; 60: 148-150.
71. INOUE J, UENO Y, WAKUI Y, NIITSUMA H, FUKUSHIMA K, YAMAGIWA Y, SHIINA M, KONDO Y, KAKAZU E, TAMAI K, OBARA N, IWASAKI T, SHIMOSEGAWA T. Four-year study of lamivudine and adefovir combination therapy in lamivudine-resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern. J Viral Hepat 2011; 18: 206-215.
72. CHOE WH, KWON SY, KIM BK, KO SY, YEON JE, BYUN KS, KIM GH, LEE CH. Tenofovir plus lamivudine as rescue therapy for adefovir-resistant chronic hepatitis B in hepatitis B e antigen-positive patients with liver cirrhosis. Liver Int 2008; 28: 814-820. (Pubitemid 351818643)
73. TANG H, RANEY AK, MCLACHLAN A. Replication of the wild type and a natural hepatitis B virus nucleocapsid promoter variant is differentially regulated by nuclear hormone receptors in cell culture. J Virol 2001; 75: 8937-8948. (Pubitemid 32851898)
74. ALCANTARA FF, TANG H, MCLACHLAN A. Functional characterization of the interferon regulatory element in the enhancer 1 region of the hepatitis B virus genome. Nucleic Acids Res 2002; 30: 2068-2075. (Pubitemid 34537605)
75. LIN Y, TANG H, NOMURA T, DORJSUREN D, HAYASHI N, WEI W, OHTA T, ROEDER R, MURAKAMI S. The hepatitis B virus X protein is a co-activator of activated transcription that modulates the transcription machinery and distal binding activators. J Biol Chem 1998; 273: 27097-27103. (Pubitemid 28500415)
76. ZOULIM F, RADENNE S, DUCERF C. Management of patients with decompensated hepatitis B virus associated [corrected] cirrhosis. Liver Transpl 2008; 14(Suppl 2): S1-S7.
77. JIA HY, LU W, ZHENG L, YING LJ, YANG YD. Efficacy of lamivudine monotherapy and combination therapy with adefovir dipivoxil for patients with hepatitis B virus-related decompensated cirrhosis. Zhonghua Gan Zang Bing Za Zhi 2011; 19: 84-87.
78. TANG H, MCLACHLAN A. Avian and mammalian hepadnaviruses have distinct transcription factor requirements for viral replication. J Virol 2002; 76: 7468-7472. (Pubitemid 34760969)
79. CHOLONGITAS E, GOULIS J, AKRIVIADIS E, PAPATHEODORIDIS GV. Hepatitis B immunoglobulin and/or nucleos(t)ide analogue(s) for prophylaxis from hepatitis B virus recurrence after liver transplantation: A systematic review. Liver Transpl 2011; 17: 1176-1190.
80. ANGUS PW, PATTERSON SJ, STRASSER SI, MCCAUGHAN GW, GANE E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
81. PATTERSON SJ, ANGUS PW. Post-liver transplant hepatitis B prophylaxis: the role of oral nucleos(t)ide analogues. Curr Opin Organ Transplant 2009; 14: 225-230.
82. DORE GJ, COOPER DA, POZNIAK AL, DEJESUS E, ZHONG L, MILLER MD, LU B, CHENG AK. Efficacy of tenofovir disoproxil fumarate in antiretroviral therapy- naive and -experienced patients coinfected with HIV-1 and hepatitis B virus. J Infect Dis 2004; 189: 1185-1192. (Pubitemid 38457242)
83. SORIANO V, TUMA P, VISPO E, LABARGA P, FERNANDEZ JV, MEDRANO J, BARREIRO P. Hepatitis B in HIV patients: what is the current treatment and what are the challenges? J HIV Ther 2009; 14: 13-8.
84. RATCLIFFE L, BEADSWORTH MB, PENNELL A, PHILLIPS M, VILAR FJ. Managing hepatitis B/HIV co-infected: adding entecavir to truvada (tenofovir disoproxil/ emtricitabine) experienced patients. AIDS 2011; 25: 1051-1056.